When was Atantares founded?

Atantares was founded in 2020 and raised its 1st funding round within a year of its incorporation.

Where is Atantares located?

Atantares is headquartered in Cambridge, United States.

Who is the current CEO of Atantares?

Xin Zhao of Atantares. They have also founded 1 company.

How many employees does Atantares have?

As of Jun 30, 2026, the latest employee count at Atantares is 6.

Is Atantares a funded company?

Atantares is a funded company, having raised a total of $14M across 3 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Feb 17, 2020.

When was the latest funding round of Atantares?

Atantares' latest funding was a $***** Seed round on Jul 31, 2023, with participation from 6 investors. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $899M in funding in 2026 to date.

Where does Atantares rank among its competitors?

Atantares ranks 6th amongst 15 active competitors, of which 9 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was 10x Science, which secured $4.8M in Apr, 2026.

Who are the top competitors of Atantares?

Atantares' top competitors include Portal Biotech, NanoMosaic and Inanovate. Among them, 10x Science secured the most recent funding round in April, 2026.

Atantares - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of precision medicines & smart diagnostic devices by fusing biochip and AI technologies. The company has developed a coagulation device that helps in monitoring specific drugs or blood products. It uses coagulation assays that monitor platelet function tests, clotting times, and viscoelasticity with a proprietary biochip platform. It provides a chimeric antigen receptor that helps in the treatment of hematological tumors, cardiac diseases, neurological disorders, and cancer. It uses an ultrasensitive immunoassay platform that provides cytokine profile data for managing CAR T-cell therapy and CRS mitigation.

Website: www.atantares.com/
Email ID: *****@atantares.com

Key Metrics

Founded Year

2020

Location

Cambridge, United States

Stage

Seed

Total Funding

$14M in 3 rounds

Latest Funding Round

Seed, Jul 31, 2023, $*****

Investors

Asia Green Fund & 7 more

Ranked

6^th among 15 active competitors

Employee Count

6 as on Jun 30, 2026

Similar Companies

Portal Biotech & 13 more

View Atantares' full profile

Atantares has raised a total funding of $14M over 3 rounds. Its first funding round was on Feb 17, 2020. Its latest funding round was a Seed round on Jul 31, 2023 for $*****. 6 investors participated in its latest round. Atantares has 8 institutional investors.

Here is the list of recent funding rounds of Atantares:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 31, 2023	2057886	Seed	7751757	4730879	4484269	7758371
Jul 01, 2020	7101852	Grant (prize money)	8502587	3829449	5750427	National Science Foundation
Feb 17, 2020	5527866	Grant (prize money)	2572805	9442523	6288240	National Science Foundation

Access funding benchmarks and valuations. Sign up today!

View details of Atantares's funding rounds and investors

The founders of Atantares are Aniruddh Sarkar, Kumaran Kolandaivelu and Xin Zhao. Xin Zhao is the CEO of Atantares.

Here are the details of Atantares' key team members:

Aniruddh Sarkar: Co-Founder of Atantares. They are also an angel investor in 1 startup.
Kumaran Kolandaivelu: Co-Founder of Atantares.
Xin Zhao: Founder & CEO of Atantares.
Contact Info: 1 email address

View details of Atantares's Founder profiles and Board Members

Atantares' employee count trend

Atantares has 6 employees as of Jun 26. Here is Atantares's employee count trend over the years:

Uncover Atantares' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Atantares include Portal Biotech, NanoMosaic and Inanovate. Here is the list of Top 10 competitors of Atantares, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Portal Biotech 2021, London (United Kingdom), Series A	Developer of biosensing technology that utilizes bioengineered nanopores to analyze proteins and metabolomics	$45.4M	Earlybird, NIF & 10 others	61/100
2nd	NanoMosaic 2018, Woburn (United States), Series A	Manufacturer of system for early disease detection and prognosis	$44.8M	RA Capital Management, Pura Vida Investments ... & 3 others	54/100
3rd	Inanovate 2006, Durham (United States), Series C	Provider of multiplexed protein quantification platform for clinical diagnostics and research	$13M	Badlands Capital, America’s Seed Fund & 3 others	42/100
4th	10x Science 2025, San Francisco (United States), Seed	Provider of AI-native protein characterization platform for biopharma	$5.3M	Initialized Capital, Y Combinator & 1 others	41/100
5th	ProteoWise 2018, New Haven (United States), Series A	Provider of a platform for the analysis of proteomics	$8.6M	Connecticut Innovations, UniWill Ventures ... & 3 others	40/100
6th	Atantares 2020, Cambridge (United States), Seed	Developer of precision medicines & smart diagnostic devices by fusing biochip and AI technologies	$14M	Frees Fund, National Science Foundation & 6 others	38/100
7th	Novilytic 2021, West Lafayette (United States), Seed	Developer of molecular recognition system to detect the quality of medicines	$3.08M	Elevate Ventures, Purdue Foundry & 3 others	38/100
8th	GenNext Technologies 2016, Montara (United States), Funding Raised	Developer of a device for protein structural analysis	-	HHS	29/100
9th	Protein Stable 2019, Leatherhead (United Kingdom), Unfunded	Provider of protein stability measurement systems for research labs	-	-	25/100
10th	Pavonis Diagnostics 2020, Edmonton (Canada), Unfunded	Provider of Visual Interference Color Assay protein detection platform	-	-	24/100